{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:53:24Z","timestamp":1791942804839,"version":"4.3.4"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Jingzhou Science and Technology Program Guidance Project","award":["2023HC99"],"award-info":[{"award-number":["2023HC99"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s10620-024-08435-4","type":"journal-article","created":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T16:01:57Z","timestamp":1716220917000},"page":"2631-2647","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Progress of Clinical Studies Targeting Claudin18.2 for the Treatment of Gastric Cancer"],"prefix":"10.1007","volume":"69","author":[{"given":"Wu-mei","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-qiang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-qiong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-yuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,20]]},"reference":[{"key":"8435_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. A Cancer J Clin. 2021;71:209\u2013249.","journal-title":"A Cancer J Clin."},{"key":"8435_CR2","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3322\/caac.21657","volume":"71","author":"SS Joshi","year":"2021","unstructured":"Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. A Cancer J Clin. 2021;71:264\u2013279.","journal-title":"A Cancer J Clin."},{"key":"8435_CR3","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","volume":"6","author":"K Shitara","year":"2020","unstructured":"Shitara K, Cutsem EV, Bang YJ et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, Advanced Gastric Cancer: The KEYNOTE-062 phase 3 randomized clinical trial. J JAMA Oncol. 2020;6:1571\u20131580.","journal-title":"J JAMA Oncol."},{"key":"8435_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","volume":"392","author":"S Kohei","year":"2018","unstructured":"Kohei S, Mustafa \u00d6, Yung JB et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. J Lancet. 2018;392:123\u2013133.","journal-title":"J Lancet."},{"key":"8435_CR5","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1083\/jcb.141.7.1539","volume":"141","author":"M Furuse","year":"1998","unstructured":"Furuse M, Fujita K, Hiiragi T et al. Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biolog. 1998;141:1539\u20131550.","journal-title":"J Cell Biolog."},{"key":"8435_CR6","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/gb-2009-10-8-235","volume":"10","author":"M Lal-Nag","year":"2009","unstructured":"Lal-Nag M, Morin PJ. The claudins. J Genome Biol. 2009;10:235.","journal-title":"J Genome Biol."},{"key":"8435_CR7","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/onc.2016.289","volume":"36","author":"S Tabaries","year":"2017","unstructured":"Tabaries S, Siegel PM. The role of claudins in cancer metastasis. J Oncogene. 2017;36:1176\u20131190.","journal-title":"J Oncogene."},{"key":"8435_CR8","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.semcdb.2014.09.022","volume":"36","author":"JR Turner","year":"2014","unstructured":"Turner JR, Buschmann MM, Romero-Calvo I et al. The role of molecular remodeling in differential regulation of tight j unction permeability. Sem Cell Dev Biol. 2014;36:204\u2013212.","journal-title":"Sem Cell Dev Biol."},{"key":"8435_CR9","doi-asserted-by":"publisher","first-page":"6123","DOI":"10.1007\/s11033-013-2724-y","volume":"40","author":"Y-J Hu","year":"2013","unstructured":"Hu Y-J, Wang Y-D, Tan F-Q et al. Regulation of paracellular permeability: factors and mechanisms. Mol Biol Rep. 2013;40:6123\u20136142.","journal-title":"Mol Biol Rep."},{"key":"8435_CR10","first-page":"367","volume":"5","author":"L Ding","year":"2013","unstructured":"Ding L, Lu Z, Lu Q et al. The claudin family of proteins in human malignancy: a clinical perspec tive. Cancer Manag Res. 2013;5:367\u2013375.","journal-title":"Cancer Manag Res."},{"key":"8435_CR11","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s00428-005-0045-9","volume":"447","author":"H Gy\u00f5rffy","year":"2005","unstructured":"Gy\u00f5rffy H, Holczbauer A, Nagy P et al. Claudin expression in Barrett\u2019s esophagus and adenocarcinoma. Virchows Archiv 2005;447:961\u2013968.","journal-title":"Virchows Archiv"},{"key":"8435_CR12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-017-0473-4","volume":"10","author":"P Singh","year":"2017","unstructured":"Singh P, Toom S, Huang Y. Anti-claudin 182 antibody as new targeted therapy for advanced gastric cancer. J Hematol Oncol. 2017;10:105.","journal-title":"J Hematol Oncol."},{"key":"8435_CR13","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nrm.2016.80","volume":"17","author":"C Zihni","year":"2016","unstructured":"Zihni C, Mills C, Matter K et al. Tight junctions: from simple barriers to multifunctional molecular gates. Nat Rev Mol Cell Biol. 2016;17:564\u2013580.","journal-title":"Nat Rev Mol Cell Biol."},{"key":"8435_CR14","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.addr.2005.01.006","volume":"57","author":"K Swisshelm","year":"2005","unstructured":"Swisshelm K, Macek R, Kubbies M. Role of claudins in tumorigenesis. Adv Drug Deliv Rev. 2005;57:919\u2013928.","journal-title":"Adv Drug Deliv Rev."},{"key":"8435_CR15","doi-asserted-by":"publisher","first-page":"7380","DOI":"10.1128\/MCB.21.21.7380-7390.2001","volume":"21","author":"T Niimi","year":"2001","unstructured":"Niimi T, Nagashima K, Ward JM et al. Claudin-18, a novel downstream target gene for the T\/EBP\/NKX2.1 homeod omain transcription factor, encodes lung- and stomach-specific isoform s through alternative splicing. Mol Cell Biol. 2001;21:7380\u201390.","journal-title":"Mol Cell Biol."},{"key":"8435_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.gene.2011.04.007","volume":"481","author":"O T\u00fcreci","year":"2011","unstructured":"T\u00fcreci O, Koslowski M, Helftenbein G et al. Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals. Gene. 2011;481:83\u201392.","journal-title":"Gene."},{"key":"8435_CR17","doi-asserted-by":"publisher","first-page":"29205","DOI":"10.1074\/jbc.M109.043752","volume":"284","author":"S Angelow","year":"2009","unstructured":"Angelow S, Yu ASL. Structure-function studies of claudin extracellular domains by cystein e-scanning mutagenesis. J Biol Chem. 2009;284:29205\u201329217.","journal-title":"J Biol Chem."},{"key":"8435_CR18","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jaci.2016.02.035","volume":"139","author":"K Sweerus","year":"2017","unstructured":"Sweerus K, Lachowicz-Scroggins M, Gordon E et al. Claudin-18 deficiency is associated with airway epithelial barrier dys function and asthma. J Allergy Clin Immunol. 2017;139:72\u201381.","journal-title":"J Allergy Clin Immunol."},{"key":"8435_CR19","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1165\/rcmb.2013-0456OC","volume":"51","author":"MJ LaFemina","year":"2014","unstructured":"LaFemina MJ, Sutherland KM, Bentley T et al. Claudin-18 deficiency results in alveolar barrier dysfunction and impa ired alveologenesis in mice. Am J Respir Cell Mol Biol. 2014;51:550\u2013558.","journal-title":"Am J Respir Cell Mol Biol."},{"key":"8435_CR20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI156409","volume":"131","author":"A Casadevall","year":"2021","unstructured":"Casadevall A, Jackson S, Semenza GL et al. The Journal of Clinical Investigation in the time of COVID-19. J Clin investig. 2021;131:e156409.","journal-title":"J Clin investig."},{"key":"8435_CR21","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.bbamcr.2016.02.015","volume":"1863","author":"S Shimobaba","year":"2016","unstructured":"Shimobaba S, Taga S, Akizuki R et al. Claudin-18 inhibits cell proliferation and motility mediated by inhibition of phosphorylation of PDK1 and Akt in human lung adenocarcinoma A 549 cells. Biochimica et Biophysica Acta. 2016;1863:1170\u20138.","journal-title":"Biochimica et Biophysica Acta."},{"key":"8435_CR22","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/his.14358","volume":"79","author":"M Iwaya","year":"2021","unstructured":"Iwaya M, Hayashi H, Nakajima T et al. Colitis-associated colorectal adenocarcinomas frequently express claud in 18 isoform 2: implications for claudin 18.2 monoclonal antibody the rapy. Histopathology. 2021;79:227\u2013237.","journal-title":"Histopathology."},{"key":"8435_CR23","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","volume":"14","author":"U Sahin","year":"2008","unstructured":"Sahin U, Koslowski M, Dhaene K et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therap eutic antibody development. Clin Cancer Res. 2008;14:7624\u20137634.","journal-title":"Clin Cancer Res."},{"key":"8435_CR24","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1053\/j.gastro.2011.10.040","volume":"142","author":"D Hayashi","year":"2012","unstructured":"Hayashi D, Tamura A, Tanaka H et al. Deficiency of claudin-18 causes paracellular H+ leakage, up-regulation of interleukin-1\u03b2, and atrophic gastritis in mice. Gastroenterology. 2012;142:292\u2013304.","journal-title":"Gastroenterology."},{"key":"8435_CR25","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1369\/0022155411420569","volume":"59","author":"M Tanaka","year":"2011","unstructured":"Tanaka M, Shibahara J, Fukushima N et al. Claudin-18 is an early-stage marker of pancreatic carcinogenesis. J Histochem Cytochem. 2011;59:942\u2013952.","journal-title":"J Histochem Cytochem."},{"key":"8435_CR26","doi-asserted-by":"publisher","first-page":"LB4001","DOI":"10.1200\/JCO.2016.34.18_suppl.LBA4001","volume":"34","author":"S-E Al-Batran","year":"2016","unstructured":"Al-Batran S-E, Schuler MH, Zvirbule Z et al. FAST: An international, multicenter, randomized, phase II trial of epi rubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GE J) adenocarcinoma. J Clin Oncol. 2016;34:LB4001.","journal-title":"J Clin Oncol."},{"key":"8435_CR27","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1126\/science.1144592","volume":"317","author":"MA Stiffler","year":"2007","unstructured":"Stiffler MA, Chen JR, Grantcharova VP et al. PDZ domain binding selectivity is optimized across the mouse proteome. Science. 2007;317:364\u20139.","journal-title":"Science."},{"key":"8435_CR28","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.3389\/fphys.2018.01942","volume":"9","author":"AA Bhat","year":"2019","unstructured":"Bhat AA, Uppada S, Achkar IW et al. Tight junction proteins and signaling pathways in cancer and inflammat ion: A functional crosstalk. Front Physiol. 2019;9:1942.","journal-title":"Front Physiol."},{"key":"8435_CR29","doi-asserted-by":"publisher","first-page":"14271","DOI":"10.18632\/aging.103457","volume":"12","author":"J Li","year":"2020","unstructured":"Li J, Zhang Y, Hu D et al. Analysis of the expression and genetic alteration of CLDN18 in gastric cancer. Aging. 2020;12:14271\u201314284.","journal-title":"Aging."},{"key":"8435_CR30","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.celrep.2015.06.020","volume":"12","author":"F Yao","year":"2015","unstructured":"Yao F, Kausalya JP, Sia YY et al. Recurrent fusion genes in gastric cancer: CLDN18-ARHGAP26 induces loss of epithelial integrity. Cell Rep. 2015;12:272\u2013285.","journal-title":"Cell Rep."},{"key":"8435_CR31","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.canlet.2017.05.033","volume":"403","author":"K Takasawa","year":"2017","unstructured":"Takasawa K, Takasawa A, Osanai M et al. Claudin-18 coupled with EGFR\/ERK signaling contributes to the malignant potentials of bile duct cancer. Cancer Lett. 2017;403:66\u201373.","journal-title":"Cancer Lett."},{"key":"8435_CR32","doi-asserted-by":"publisher","first-page":"G1106","DOI":"10.1152\/ajpgi.00158.2007","volume":"293","author":"B Jovov","year":"2007","unstructured":"Jovov B, Van Itallie CM, Shaheen NJ et al. Claudin-18: a dominant tight junction protein in Barrett\u2019s esophagus and likely contributor to its acid resistance. Am J Physiol-Gastrointest Liver Physiol. 2007;293:G1106\u2013G1113.","journal-title":"Am J Physiol-Gastrointest Liver Physiol."},{"key":"8435_CR33","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00428-019-02624-7","volume":"475","author":"M Dottermusch","year":"2019","unstructured":"Dottermusch M, Kr\u00fcger S, Behrens H-M et al. Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: results from a large Caucasian cohort study. Virchows Archiv. 2019;475:563\u2013571.","journal-title":"Virchows Archiv."},{"key":"8435_CR34","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.canlet.2018.06.040","volume":"433","author":"K-H Liang","year":"2018","unstructured":"Liang K-H, Tso H-C, Hung S-H et al. Extracellular domain of EpCAM enhances tumor progression through EGFR signaling in colon cancer cells. Cancer Lett. 2018;433:165\u2013175.","journal-title":"Cancer Lett."},{"key":"8435_CR35","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12943-015-0387-0","volume":"14","author":"Z Lu","year":"2015","unstructured":"Lu Z, Kim DH, Fan J et al. A non-tight junction function of claudin-7-Interaction with integrin signaling in suppressing lung cancer cell proliferation and detachment. Mol Cancer. 2015;14:120.","journal-title":"Mol Cancer."},{"key":"8435_CR36","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1053\/j.gastro.2018.08.041","volume":"155","author":"SJ Hagen","year":"2018","unstructured":"Hagen SJ, Ang L-H, Zheng Y et al. Loss of tight junction protein Claudin 18 promotes progressive neoplas ia development in mouse stomach. Gastroenterology. 2018;155:1852\u20131867.","journal-title":"Gastroenterology."},{"key":"8435_CR37","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/path.1922","volume":"208","author":"Y Sanada","year":"2006","unstructured":"Sanada Y, Oue N, Mitani Y et al. Down-regulation of the claudin-18 gene, identified through serial analysis of gene expression data analysis, in gastric cancer with an intestinal phenotype. J Pathol. 2006;208:633\u2013642.","journal-title":"J Pathol."},{"key":"8435_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074757","volume":"8","author":"T Oshima","year":"2013","unstructured":"Oshima T, Shan J, Okugawa T et al. Down-regulation of claudin-18 is associated with the proliferative and invasive potential of gastric cancer at the invasive front. PloS ONE. 2013;8:e74757.","journal-title":"PloS ONE."},{"key":"8435_CR39","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1002\/jcb.23095","volume":"112","author":"T Ito","year":"2011","unstructured":"Ito T, Kojima T, Yamaguchi H et al. Transcriptional regulation of claudin-18 via specific protein kinase C signaling pathways and modification of DNA methylation in human pancr eatic cancer cells. J Cell Biochem. 2011;112:1761\u20131772.","journal-title":"J Cell Biochem."},{"key":"8435_CR40","doi-asserted-by":"publisher","first-page":"G336","DOI":"10.1152\/ajpgi.00328.2007","volume":"294","author":"K Yano","year":"2008","unstructured":"Yano K, Imaeda T, Niimi T. Transcriptional activation of the human claudin-18 gene promoter through two AP-1 motifs in PMA-stimulated MKN45 gastric cancer cells. Am J Physiol-Gastrointest Liver Physiol. 2008;294:G336\u2013G343.","journal-title":"Am J Physiol-Gastrointest Liver Physiol."},{"key":"8435_CR41","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1111\/hepr.12500","volume":"45","author":"H Sun","year":"2015","unstructured":"Sun H, Cui C, Xiao F et al. miR-486 regulates metastasis and chemosensitivity in hepatocellular ca rcinoma by targeting CLDN10 and CITRON. Hepatol Res. 2015;45:1312\u20131322.","journal-title":"Hepatol Res."},{"key":"8435_CR42","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1158\/0008-5472.CAN-04-1187","volume":"64","author":"M Koslowski","year":"2004","unstructured":"Koslowski M, Bell C, Seitz G et al. Frequent nonrandom activation of germ-line genes in human cancer. Cancer Res. 2004;64:5988\u20135993.","journal-title":"Cancer Res."},{"key":"8435_CR43","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1007\/s10620-014-3107-5","volume":"59","author":"S-J Zhang","year":"2014","unstructured":"Zhang S-J, Feng J-F, Wang L et al. miR-1303 targets claudin-18 gene to modulate proliferation and invasion of gastric cancer cells. Dig Dis Sci. 2014;59:1754\u20131763. https:\/\/doi.org\/10.1007\/s10620-014-3107-5.","journal-title":"Dig Dis Sci."},{"key":"8435_CR44","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41416-019-0508-4","volume":"121","author":"I Coati","year":"2019","unstructured":"Coati I, Lotz G, Fanelli GN et al. Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue mi croarray study of 523 molecularly profiled cases. Br J Cancer. 2019;121:257\u2013263.","journal-title":"Br J Cancer."},{"key":"8435_CR45","doi-asserted-by":"publisher","first-page":"8420","DOI":"10.1038\/s41598-019-44874-0","volume":"9","author":"G Zhu","year":"2019","unstructured":"Zhu G, Foletti D, Liu X et al. Targeting CLDN18.2 by CD3 bispecific and ADC modalities for the treatments of gastric and pancreatic cancer. Sci Rep. 2019;9:8420.","journal-title":"Sci Rep."},{"key":"8435_CR46","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1007\/s12094-020-02380-0","volume":"22","author":"A Arnold","year":"2020","unstructured":"Arnold A, Daum S, van Winterfeld M et al. Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas. Clin Transl Oncol. 2020;22:2357\u20132363.","journal-title":"Clin Transl Oncol."},{"key":"8435_CR47","doi-asserted-by":"publisher","first-page":"1967080","DOI":"10.1080\/21688370.2021.1967080","volume":"10","author":"D Kyuno","year":"2022","unstructured":"Kyuno D, Takasawa A, Takasawa K et al. Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials. Tissue Barriers 2022;10:1967080.","journal-title":"Tissue Barriers"},{"key":"8435_CR48","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1021\/acs.analchem.0c04055","volume":"93","author":"L Fan","year":"2021","unstructured":"Fan L, Chong X, Zhao M et al. Ultrasensitive gastric cancer circulating tumor cellular CLDN18.2 RNA Detection based on a molecular beacon. Anal Chem. 2021;93:665\u2013670.","journal-title":"Anal Chem."},{"key":"8435_CR49","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1002\/ijc.28857","volume":"135","author":"P Micke","year":"2014","unstructured":"Micke P, Mattsson JSM, Edlund K et al. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer. Int J Cancer. 2014;135:2206\u20132214.","journal-title":"Int J Cancer."},{"key":"8435_CR50","first-page":"3665","volume":"19","author":"V Moentenich","year":"2020","unstructured":"Moentenich V, Gebauer F, Comut E et al. Claudin 18.2 expression in esophageal adenocarcinoma and its potential impact on future treatment strategies. Oncol Lett. 2020;19:3665\u20133670.","journal-title":"Oncol Lett."},{"key":"8435_CR51","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1097\/PAS.0000000000001847","volume":"46","author":"T Kiyokawa","year":"2022","unstructured":"Kiyokawa T, Hoang L, Pesci A et al. Claudin-18 as a promising surrogate marker for endocervical gastric-type carcinoma. Am J Surg Pathol. 2022;46:628\u2013636.","journal-title":"Am J Surg Pathol."},{"key":"8435_CR52","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1093\/jjco\/hyz068","volume":"49","author":"C Rohde","year":"2019","unstructured":"Rohde C, Yamaguchi R, Mukhina S et al. Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma. Japanese J Clin Oncol. 2019;49:870\u2013876.","journal-title":"Japanese J Clin Oncol."},{"key":"8435_CR53","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3390\/jpm11111095","volume":"11","author":"A Pellino","year":"2021","unstructured":"Pellino A, Brignola S, Riello E et al. Association of CLDN18 protein expression with clinicopathological features and prognosis in advanced gastric and gastroesophageal junction A denocarcinomas. J Pers Med. 2021;11:1095.","journal-title":"J Pers Med."},{"key":"8435_CR54","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.canlet.2020.09.019","volume":"495","author":"J Yang","year":"2020","unstructured":"Yang J, Liu Z, Zeng B et al. Epstein-Barr virus-associated gastric cancer: A distinct subtype. Cancer Lett. 2020;495:191\u2013199.","journal-title":"Cancer Lett."},{"key":"8435_CR55","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1369\/jhc.2009.953810","volume":"57","author":"A Shinozaki","year":"2009","unstructured":"Shinozaki A, Ushiku T, Morikawa T et al. Epstein-Barr virus-associated gastric carcinoma: a distinct carcinoma of gastric phenotype by claudin expression profiling. J Histochem Cytochem 2009;57:775\u2013785.","journal-title":"J Histochem Cytochem"},{"key":"8435_CR56","doi-asserted-by":"crossref","unstructured":"Jia K, Chen Y, Sun Y, et al. Multiplex immunohistochemistry defines the tumor immune microenvironme nt and immunotherapeutic outcome in CLDN18.2-positive gastric cancer. BMC Med. 2022;20.","DOI":"10.1186\/s12916-022-02421-1"},{"key":"8435_CR57","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.21037\/jgo-20-344","volume":"11","author":"B Xu","year":"2020","unstructured":"Xu B, Liu F, Liu Q et al. Highly expressed Claudin182 as a potential therapeutic target in advanced gastric signet-ring cell carcinoma (SRCC). J Gastrointest Oncol. 2020;11:1431\u20131439.","journal-title":"J Gastrointest Oncol."},{"key":"8435_CR58","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/j.1349-7006.2007.00490.x","volume":"98","author":"Y Matsuda","year":"2007","unstructured":"Matsuda Y, Semba S, Ueda J et al. Gastric and intestinal claudin expression at the invasive front of gastric carcinoma. Cancer Sci. 2007;98:1014\u20131019.","journal-title":"Cancer Sci."},{"key":"8435_CR59","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ijsu.2013.11.022","volume":"12","author":"K-H Jun","year":"2014","unstructured":"Jun K-H, Kim J-H, Jung J-H et al. Expression of claudin-7 and loss of claudin-18 correlate with poor pro gnosis in gastric cancer. Int J Surg. 2014;12:156\u2013162.","journal-title":"Int J Surg."},{"key":"8435_CR60","doi-asserted-by":"publisher","first-page":"6973","DOI":"10.21873\/anticanres.13919","volume":"39","author":"JH Baek","year":"2019","unstructured":"Baek JH, Park DJ, Kim GY et al. Clinical implications of Claudin18.2 expression in patients with gastric cancer. Anticancer Res. 2019;39:6973\u20136979.","journal-title":"Anticancer Res."},{"key":"8435_CR61","doi-asserted-by":"publisher","first-page":"263","DOI":"10.21147\/j.issn.1000-9604.2020.02.13","volume":"32","author":"J Zhang","year":"2020","unstructured":"Zhang J, Dong R, Shen L. Evaluation and reflection on claudin 18.2 targeting therapy in advanced gastric cancer. Chin J Cancer Res 2020;32:263\u2013270.","journal-title":"Chin J Cancer Res"},{"key":"8435_CR62","doi-asserted-by":"publisher","first-page":"100762","DOI":"10.1016\/j.esmoop.2022.100762","volume":"8","author":"Y Kubota","year":"2023","unstructured":"Kubota Y, Kawazoe A, Mishima S et al. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer. ESMO Open. 2023;8:100762.","journal-title":"ESMO Open."},{"key":"8435_CR63","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202\u2013209.","DOI":"10.1038\/nature13480"},{"key":"8435_CR64","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.1038\/s41467-018-06747-4","volume":"9","author":"H Yang","year":"2018","unstructured":"Yang H, Hong D, Cho SY et al. RhoGAP domain-containing fusions and PPAPDC1A fusions are recurrent and prognostic in diffuse gastric cancer. Nat Commun. 2018;9:4439.","journal-title":"Nat Commun."},{"key":"8435_CR65","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1038\/s41467-018-04907-0","volume":"9","author":"Y Shu","year":"2018","unstructured":"Shu Y, Zhang W, Hou Q et al. Prognostic significance of frequent CLDN18-ARHGAP26\/6 fusion in gastric signet-ring cell cancer. Nat Commun. 2018;9:2447.","journal-title":"Nat Commun."},{"key":"8435_CR66","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1111\/cas.13967","volume":"110","author":"I Nakayama","year":"2019","unstructured":"Nakayama I, Shinozaki E, Sakata S et al. Enrichment of CLDN18-ARHGAP fusion gene in gastric cancers in young adults. Cancer Sci. 2019;110:1352\u20131363.","journal-title":"Cancer Sci."},{"key":"8435_CR67","doi-asserted-by":"publisher","first-page":"29336","DOI":"10.18632\/oncotarget.25464","volume":"9","author":"A Tanaka","year":"2018","unstructured":"Tanaka A, Ishikawa S, Ushiku T et al. Frequent CLDN18-ARHGAP fusion in highly metastatic diffuse-type gastric cancer with relatively early onset. Oncotarget. 2018;9:29336\u201329350.","journal-title":"Oncotarget."},{"key":"8435_CR68","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s10120-018-0895-x","volume":"22","author":"X Cheng","year":"2019","unstructured":"Cheng X, Yu S, Wang Y et al. The role of oxaliplatin in the adjuvant setting of different Lauren\u2019s type of gastric adenocarcinoma after D2 gastrectomy: a real-world study. Gastric Cancer. 2019;22:587\u2013597.","journal-title":"Gastric Cancer."},{"key":"8435_CR69","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.stem.2018.09.016","volume":"23","author":"HHN Yan","year":"2018","unstructured":"Yan HHN, Siu HC, Law S et al. A comprehensive human gastric cancer organoid biobank captures tumor subtype heterogeneity and enables therapeutic screening. Cell Stem Cell. 2018;23:882\u2013897.","journal-title":"Cell Stem Cell."},{"key":"8435_CR70","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejca.2018.05.007","volume":"100","author":"U Sahin","year":"2018","unstructured":"Sahin U, Schuler M, Richly H et al. A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer. Eur J Cancer. 2018;100:17\u201326.","journal-title":"Eur J Cancer."},{"key":"8435_CR71","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1523096","volume":"8","author":"\u04e6 T\u00fcreci","year":"2018","unstructured":"T\u00fcreci \u04e6, Mitnacht-Kraus R, W\u00f6ll S et al. Characterization of zolbetuximab in pancreatic cancer models. Oncoimmunology. 2018;8:e1523096.","journal-title":"Oncoimmunology."},{"key":"8435_CR72","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1093\/annonc\/mdx051","volume":"28","author":"F Lordick","year":"2017","unstructured":"Lordick F, Shitara K, Janjigian YY. New agents on the horizon in gastric cancer. Ann Oncol. 2017;28:1767\u20131775.","journal-title":"Ann Oncol."},{"key":"8435_CR73","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/ijc.28400","volume":"134","author":"S W\u00f6ll","year":"2014","unstructured":"W\u00f6ll S, Schlitter AM, Dhaene K et al. Claudin 182 is a target for IMAB362 antibody in pancreatic neoplasms. Int J Cancer. 2014;134:731\u20139.","journal-title":"Int J Cancer."},{"key":"8435_CR74","doi-asserted-by":"publisher","first-page":"48","DOI":"10.21037\/cco.2017.07.02","volume":"6","author":"TG Lyons","year":"2017","unstructured":"Lyons TG, Ku GY. Systemic therapy for esophagogastric cancer: targeted therapies. Chin Clin Oncol. 2017;6:48\u201348.","journal-title":"Chin Clin Oncol."},{"key":"8435_CR75","doi-asserted-by":"publisher","first-page":"e15079","DOI":"10.1200\/jco.2015.33.15_suppl.e15079","volume":"33","author":"U Sahin","year":"2015","unstructured":"Sahin U, Al-Batran S-E, Hozaeel W et al. IMAB362 plus zoledronic acid (ZA) and interleukin-2 (IL-2) in patients (pts) with advanced gastroesophageal cancer (GEC): clinical activity and safety data from the PILOT phase I trial. J Clin Oncol. 2015;33:e15079.","journal-title":"J Clin Oncol."},{"key":"8435_CR76","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1093\/annonc\/mdz199","volume":"30","author":"O T\u00fcreci","year":"2019","unstructured":"T\u00fcreci O, Sahin U, Schulze-Bergkamen H et al. A multicentre, phase IIa study of zolbetuximab as a single agent in pa tients with recurrent or refractory advanced adenocarcinoma of the sto mach or lower oesophagus: the MONO study. Ann Oncol. 2019;30:1487\u20131495.","journal-title":"Ann Oncol."},{"key":"8435_CR77","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.annonc.2021.02.005","volume":"32","author":"U Sahin","year":"2021","unstructured":"Sahin U, T\u00fcreci \u00d6, Manikhas G et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX v ersus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 2021;32:609\u2013619.","journal-title":"Ann Oncol."},{"key":"8435_CR78","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"Y-J Bang","year":"2010","unstructured":"Bang Y-J, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687\u2013697.","journal-title":"Lancet."},{"key":"8435_CR79","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang Y-J et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-ne gative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicen tre, randomised, double-blind, phase 3 trial. Lancet. 2023;401:1655\u20131668.","journal-title":"Lancet."},{"key":"8435_CR80","doi-asserted-by":"publisher","first-page":"3882","DOI":"10.1158\/1078-0432.CCR-23-0204","volume":"29","author":"SJ Klempner","year":"2023","unstructured":"Klempner SJ, Lee K-W, Shitara K et al. ILUSTRO: Phase II multicohort trial of zolbetuximab in patients with advanced or metastatic Claudin 182\u2013positive gastric or gastroesophagea l junction adenocarcinoma. Clin Cancer Res. 2023;29:3882\u20133891.","journal-title":"Clin Cancer Res."},{"key":"8435_CR81","doi-asserted-by":"publisher","first-page":"1238009","DOI":"10.3389\/fphar.2023.1238009","volume":"14","author":"Y Huang","year":"2023","unstructured":"Huang Y, You M, Wu Q et al. Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first -line treatment for CLDN182-positive, HER2-negative advanced gastric or gastroesophageal adenocarcinoma. Front Pharmacol. 2023;14:1238009.","journal-title":"Front Pharmacol."},{"key":"8435_CR82","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophage al junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29:2133\u20132141.","journal-title":"Nat Med."},{"key":"8435_CR83","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.1158\/1538-7445.AM2020-5183","volume":"80","author":"F Teng","year":"2020","unstructured":"Teng F, Gu Y, Chai H et al. Abstract 5183: The preclinical characterization of TST001, a novel humanized anti-claudin18.2 mAb with enhanced binding affinity and anti-tumor activity. Cancer Res. 2020;80:5183\u20135183.","journal-title":"Cancer Res."},{"key":"8435_CR84","doi-asserted-by":"publisher","first-page":"S858","DOI":"10.1016\/j.annonc.2023.09.1437","volume":"34","author":"L Shen","year":"2023","unstructured":"Shen L, Liu D, Li N et al. 1524P First-line TST001 plus capecitabine and oxaliplatin (CAPOX) for advanced G\/GEJ cancer with CLDN18.2 positive overall survival data fro m study transtar102-Cohort C. Ann Oncol. 2023;34:S858\u2013S859.","journal-title":"Ann Oncol."},{"key":"8435_CR85","doi-asserted-by":"publisher","first-page":"S873","DOI":"10.1016\/j.annonc.2023.09.1472","volume":"34","author":"X Qian","year":"2023","unstructured":"Qian X, Teng F, Guo H et al. 1560P Osemitamab (TST001): An ADCC enhanced humanized anti-CLDN18.2 ma b, demonstrated improved efficacy in combination with anti-PD-L1\/PD-1 mab and oxaliplatin\/5-FU in preclinical tumor models. Ann Oncol. 2023;34:S873.","journal-title":"Ann Oncol."},{"key":"8435_CR86","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1200\/JCO.2023.41.4_suppl.391","volume":"41","author":"J Li","year":"2023","unstructured":"Li J, Pan H, Liu T et al. A multicenter, phase 1 study of AB011, a recombinant humanized anti-CL DN18.2 monoclonal antibody, as monotherapy and combined with capecitabine and oxaliplatin (CAPOX) in patients with advanced solid tumors. J Clin Oncol. 2023;41:391\u2013391.","journal-title":"J Clin Oncol."},{"key":"8435_CR87","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1200\/JCO.2023.41.4_suppl.397","volume":"41","author":"M Zhang","year":"2023","unstructured":"Zhang M, Gong J, Wang J et al. A phase I\/II study of ASKB589 (anti-claudin 18.2 [CLDN18.2] monoclonal antibody) in patients with solid tumors. J Clin Oncol. 2023;41:397\u2013397.","journal-title":"J Clin Oncol."},{"key":"8435_CR88","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1200\/JCO.2023.41.16_suppl.2537","volume":"41","author":"S Sharma","year":"2023","unstructured":"Sharma S, Starodub A, Xu N et al. Preliminary results of a phase 1\/2, first-in-human, open-label, dose escalation study of ZL-1211 (anti-Claudin 18.2 mAb) in patients with un resectable or metastatic solid tumors. J Clin Oncol. 2023;41:2537\u20132537.","journal-title":"J Clin Oncol."},{"key":"8435_CR89","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1200\/JCO.2023.41.4_suppl.798","volume":"41","author":"J Huang","year":"2023","unstructured":"Huang J, Zhang B, Wang Y et al. Safety and preliminary efficacy of MIL93 in patients with advanced sol id tumors: The monotherapy part of a phase 1 trial. J Clin Oncol. 2023;41:798\u2013798.","journal-title":"J Clin Oncol."},{"key":"8435_CR90","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","volume":"36","author":"R Grosser","year":"2019","unstructured":"Grosser R, Cherkassky L, Chintala N et al. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell. 2019;36:471\u2013482.","journal-title":"Cancer Cell."},{"key":"8435_CR91","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/jnci\/djy134","volume":"111","author":"H Jiang","year":"2019","unstructured":"Jiang H, Shi Z, Wang P et al. Claudin18.2-specific chimeric antigen receptor engineered T cells for the treatment of gastric cancer. J Natl Cancer Inst. 2019;111:409\u2013418.","journal-title":"J Natl Cancer Inst."},{"key":"8435_CR92","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi C, Gong J, Li J et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med. 2022;28:1189\u20131198.","journal-title":"Nat Med."},{"key":"8435_CR93","doi-asserted-by":"publisher","first-page":"S638","DOI":"10.1016\/j.annonc.2023.09.2193","volume":"34","author":"S Qin","year":"2023","unstructured":"Qin S, Tian W, Li M et al. 1054P A phase Ia study to evaluate the safety, tolerability, pharmacok inetics and preliminary efficacy of a modular CLDN18.2-targeting PG CA R-T therapy (IBI345) in patients with CLDN182+ solid tumors. Ann Oncol. 2023;34:S638.","journal-title":"Ann Oncol."},{"key":"8435_CR94","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40364-022-00385-1","volume":"10","author":"W Cao","year":"2022","unstructured":"Cao W, Xing H, Li Y et al. Claudin182 is a novel molecular biomarker for tumor-targeted immunotherapy. Biomark Res. 2022;10:38.","journal-title":"Biomark Res."},{"key":"8435_CR95","doi-asserted-by":"crossref","unstructured":"NS NSRR, AD ADSS, SH S-hCC, et al. An anti-B cell maturation antigen bispecific antibody for multiple myeloma. 2015;5288\u20135291.","DOI":"10.1021\/jacs.5b01876"},{"key":"8435_CR96","doi-asserted-by":"crossref","unstructured":"Zhu G, Ye J, Ma J, et al. Abstract 534: Discovery of an anti-claudin182\/anti-PD-L1 bispecific a ntibody SPX-301 in the SMARTOPTM format. Cancer Res. 80:534\u2013534.","DOI":"10.1158\/1538-7445.AM2020-534"},{"key":"8435_CR97","doi-asserted-by":"publisher","first-page":"S928","DOI":"10.1016\/j.annonc.2020.08.2002","volume":"31","author":"F Lordick","year":"2020","unstructured":"Lordick F, Chao J, Bux\u00f2 E et al. 1496TiP Phase I study evaluating safety and tolerability of AMG 910, a half-life extended bispecific T cell engager targeting claudin-18.2 ( CLDN18.2) in gastric and gastroesophageal junction (G\/GEJ) adenocarcinoma. Ann Oncol. 2020;31:S928\u2013S929.","journal-title":"Ann Oncol."},{"key":"8435_CR98","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.pharmthera.2017.08.005","volume":"182","author":"Z Wu","year":"2018","unstructured":"Wu Z, Cheung NV. T cell engaging bispecific antibody (T-BsAb): From technology to thera peutics. Pharmacol Ther. 2018;182:161\u2013175.","journal-title":"Pharmacol Ther."},{"key":"8435_CR99","doi-asserted-by":"publisher","first-page":"6977","DOI":"10.2147\/CMAR.S330637","volume":"13","author":"J Liang","year":"2021","unstructured":"Liang J, Zhang H, Huang Y et al. A CLDN182-targeting bispecific t cell co-stimulatory activator for cancer immunotherapy. Cancer Manag Res. 2021;13:6977\u20136987.","journal-title":"Cancer Manag Res."},{"key":"8435_CR100","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20150089","volume":"35","author":"C Peters","year":"2015","unstructured":"Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015;35:e00225.","journal-title":"Biosci Rep."},{"key":"8435_CR101","doi-asserted-by":"publisher","first-page":"434420","DOI":"10.1200\/JCO.2023.41.36_suppl.434420","volume":"41","author":"R-H Xu","year":"2023","unstructured":"Xu R-H, Ruan D-Y, Zhang D-S et al. A phase 1 trial of claudin 182-specific antibody-drug conjugate CMG90 1 in patients with advanced gastric\/gastroesophageal junction cancer. J Clin Oncol. 2023;41:434420.","journal-title":"J Clin Oncol."},{"key":"8435_CR102","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1200\/JCO.2023.41.16_suppl.3016","volume":"41","author":"Y Wang","year":"2023","unstructured":"Wang Y, Gong J, Lin R et al. First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 182 in patients with resistant\/refractory solid tumors. J Clin Oncol. 2023;41:3016.","journal-title":"J Clin Oncol."},{"key":"8435_CR103","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1021\/acs.molpharmaceut.1c00947","volume":"19","author":"C Zhao","year":"2022","unstructured":"Zhao C, Rong Z, Ding J et al. Targeting Claudin 18.2 using a highly specific antibody enables cancer diagnosis and guided surgery. Mol Pharm. 2022;19:3530\u20133541.","journal-title":"Mol Pharm."},{"key":"8435_CR104","doi-asserted-by":"publisher","first-page":"116450","DOI":"10.1016\/j.jep.2023.116450","volume":"311","author":"X Xu","year":"2023","unstructured":"Xu X, Li Y, Zhang R et al. Jianpi Yangzheng decoction suppresses gastric cancer progression via m odulating the miR-448\/CLDN18.2 mediated YAP\/TAZ signaling. J Ethnopharmacol. 2023;311:116450.","journal-title":"J Ethnopharmacol."},{"key":"8435_CR105","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/annonc\/mdy269.101","volume":"29","author":"D Moran","year":"2018","unstructured":"Moran D, Maurus D, Rohde C. Prevalence of CLDN182, HER2 and PD-L1 in gastric cancer samples. Ann Oncol 2018;29:32.","journal-title":"Ann Oncol"},{"key":"8435_CR106","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1111\/cas.15684","volume":"14","author":"K Shitara","year":"2023","unstructured":"Shitara K, Kawazoe A, Hirakawa A. Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma. Cancer Sci 2023;14:1606\u20131615.","journal-title":"Cancer Sci"},{"key":"8435_CR107","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1200\/JCO.2019.37.15_suppl.2509","volume":"37","author":"X Zhan","year":"2019","unstructured":"Zhan X, Wang B, Li Z et al. Phase I trial of Claudin 18.2-specific chimeric antigen receptor T cel ls for advanced gastric and pancreatic adenocarcinoma. J Clin Oncol. 2019;37:2509\u20132509.","journal-title":"J Clin Oncol."},{"key":"8435_CR108","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1200\/JCO.2022.40.16_suppl.2568","volume":"40","author":"J Gong","year":"2022","unstructured":"Gong J, Shen L, Hou J et al. Safety results of Q-1802, a Claudin18.2\/PD-L1 bsABs, in patients with relapsed or refractory solid tumors in a phase 1 study. J Clin Oncol. 2022;40:2568\u20132568.","journal-title":"J Clin Oncol."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-024-08435-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-024-08435-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-024-08435-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T02:06:24Z","timestamp":1721354784000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-024-08435-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,20]]},"references-count":108,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["8435"],"URL":"https:\/\/doi.org\/10.1007\/s10620-024-08435-4","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,20]]},"assertion":[{"value":"25 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}